|
|
Volumn 14, Issue 13, 2013, Pages 1245-1246
|
|
Axitinib in advanced renal-cell carcinoma
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AXITINIB;
SORAFENIB;
ADULT;
AGED;
ALOPECIA;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CONTROLLED STUDY;
DECREASED APPETITE;
DIARRHEA;
DOSE RESPONSE;
DRUG DOSE COMPARISON;
DRUG DOSE INCREASE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG WITHDRAWAL;
DYSPHONIA;
ERYTHEMA;
FEMALE;
HAND FOOT SYNDROME;
HUMAN;
HYPERTENSION;
HYPOTHYROIDISM;
KIDNEY CARCINOMA;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS POTENTIAL;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
RASH;
SIDE EFFECT;
UPPER ABDOMINAL PAIN;
WEIGHT REDUCTION;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
FEMALE;
HUMANS;
IMIDAZOLES;
INDAZOLES;
KIDNEY NEOPLASMS;
MALE;
NIACINAMIDE;
PHENYLUREA COMPOUNDS;
|
|
EID: 84888128437
PISSN: 14702045
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/S1470-2045(13)70499-6 Document Type: Letter |
|
Times cited : (3)
|
|
References (6)
|
